Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i>
Chronic infection and inflammation are the primary causes of declining lung function in Cystic Fibrosis (CF) patients. ORKAMBI<sup>®</sup> (Lumacaftor-Ivacaftor) is an approved combination therapy for Cystic Fibrosis (CF) patients bearing the most common mutation, F508del, in th...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/2/334 |